Filing Details
- Accession Number:
- 0001562180-23-008222
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-12-07 21:03:12
- Reporting Period:
- 2023-12-05
- Accepted Time:
- 2023-12-07 21:03:12
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1314102 | Eyepoint Pharmaceuticals Inc. | EYPT | Laboratory Analytical Instruments (3826) | 262774444 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1840407 | Ye Liu | 56F, One Museum Place, 669 Xin Zha Road Jing'An District Shanghai 200041 | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.001 Par Value | Disposition | 2023-12-05 | 733,758 | $19.91 | 2,276,963 | No | 4 | S | Indirect | Ocumension Therapeutics |
| Common Stock, $0.001 Par Value | Disposition | 2023-12-06 | 266,242 | $18.41 | 2,010,721 | No | 4 | S | Indirect | Ocumension Therapeutics |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Indirect | Ocumension Therapeutics |
| No | 4 | S | Indirect | Ocumension Therapeutics |
Footnotes
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.80 to $20.38. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The shares are held by Ocumension Therapeutics. The reporting person is Chief Executive Officer and a Director of Ocumension Therapeutics. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.17 to $18.49. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Billionaire Hedge Funds
